BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the influence of severe renal impairment on the pharmacokinetics (PK),
safety, and selected pharmacodynamic (PD) parameters of BI 1744 CL (30 μg administered by
inhalation with the Respimat® Inhaler)